Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: MON 414-436-HPT Axis Biology & Action
Monday, June 17, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board MON-430
James England*1, Helen Atkinson1, Amy Rafferty1, Karen Bedford2, Laszlo Karsai1 and Stephen L Atkin3
1Hull and East Yorkshire Hospitals NHS Trust, Hull, United Kingdom, 2Hull & East Yorkshire Trust, Hull, United Kingdom, 3Hull York Medical School, E Yorkshire, United Kingdom

Helen Atkinson*, R James A England*, Amy Rafferty*, Karen Bedford, Laszlo Karsai, Stephen L Atkin

*Department of Otolaryngology Head and Neck Surgery, Castle Hill Hospital, Cottingham, East Yorks, UK, HU16 5JQ


 Context: Somatostatin analogues are commercially available and used for the management of acromegaly and neuroendocrine tumours, but the expression of the receptors as a target in thyroid disease has not been explored. 

Objective: To assess somatostatin (SST) and somatostatin receptor (SSTR1-5) expression in both normal and thyroid disorders as a potential target for somatostatin analogue therapy. 

Design: Sixty seven thyroid tissue specimens were reviewed; 12 differentiated thyroid carcinomas, 14 follicular adenomas, 17 multinodular goitres, 14 Graves disease, 10 Hashimotos thyroiditis specimens and five normal thyroid tissue. Tissue was immunostained for SST and SSTR1-5. Positivity and the degree of positivity were recorded by double blinded observers.

Results: Somatostatin receptor expression was highly expressed in normal tissue for SSTR1, 3, 4 and 5 (5 of 5, 4 of 5, 4 of 5 and 5 of 5 respectively) whilst SST and SSTR 2a and b were not expressed at all.  The commonest receptor expressed for all pathological subtypes grouped together was SSTR2b, (63 specimens). The commonest receptor expressed in differentiated thyroid cancer was SSTR5 (11 of 12 specimens), and SSTR2b (53 of 55 specimens) in benign disease. SSTR5 was significantly under expressed in Grave’s disease (p<0.05).

Conclusion: This study illustrates that SSTR 1, 3, 4 and 5 are highly expressed in normal, benign and malignant thyroid tissue, SSTR 2a and 2b appear absent in normal tissue and present in benign and malignant thyroid tissue  (p<0.02), suggesting that focussed SSTR2 treatment may be a potential therapeutic target.

Nothing to Disclose: JE, HA, AR, KB, LK, SLA

*Please take note of The Endocrine Society's News Embargo Policy at